{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:56:02Z","timestamp":1791510962610,"version":"4.3.4"},"reference-count":27,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"11","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Glob Oncol"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>Patients with diffuse large B-cell lymphoma (DLBCL) who are treated in low-resource settings have inferior outcomes compared with those in high-resource settings. Rituximab, an anti-CD20 monoclonal antibody, when combined with chemotherapy, improves overall survival (OS) for DLBCL. However, in part due to the limited availability of infusion centers in low-resource countries, rituximab is rarely used. Subcutaneous rituximab (sqR) is a potential solution; however, its safety and efficacy have not been tested in low-income countries.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>This open-label phase I study enrolled patients 18 years or older with newly diagnosed DLBCL. The first cohort (n = 6) received intravenous rituximab plus CHOP. This cohort received sqR for subsequent cycles. The second cohort (n = 12) received sqR plus CHOP for all cycles. Safety and tolerability were evaluated; secondary outcomes included response rates and treatment completion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Between October 25, 2019, and October 7, 2022, 18 patients, with a median age of 36.5 years, were enrolled; 10 were male, and 10 presented with advanced-stage disease. The most common hematologic toxicity was neutropenia (n = 9, 50%). Fifteen of the 18 participants completed treatment; 14 (93.3%) patients achieved a complete response, and one patient (6.7%) had a partial response. The OS and progression-free survival (PFS) at 12 months were 83% (95% CI, 68 to 100) and 67% (95% CI, 48 to 92), respectively. The OS and PFS at 24 months were 66% (95% CI, 47 to 92) and 67% (95% CI, 48 to 92), respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>As demonstrated in other parts of the world, sqR together with CHOP was safe, well-tolerated, and efficacious among Ugandan patients with DLBCL. The very high OS rates are nearly double those of historical controls and comparable with outcomes expected in resource-rich settings. This study demonstrated the feasibility, safety, and efficacy of sqR-CHOP, increased the research infrastructure in Uganda, and will improve care in other resource-limited settings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/go-24-00489","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T19:59:39Z","timestamp":1743796779000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":3,"title":["Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda"],"prefix":"10.1200","clinical-trial-number":[{"clinical-trial-number":"nct03864419","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4981-0376","authenticated-orcid":true,"given":"Manoj P.","family":"Menon","sequence":"first","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9227-4030","authenticated-orcid":false,"given":"Henry","family":"Ddungu","sequence":"additional","affiliation":[{"name":"Uganda Cancer Institute, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin R.","family":"Mubiru","sequence":"additional","affiliation":[{"name":"Hutchinson Centre Research Institute\u2014Uganda, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott V.","family":"Adams","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Asea","sequence":"additional","affiliation":[{"name":"Hutchinson Centre Research Institute\u2014Uganda, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Namagembe","sequence":"additional","affiliation":[{"name":"Hutchinson Centre Research Institute\u2014Uganda, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prossy","family":"Namuli","sequence":"additional","affiliation":[{"name":"Hutchinson Centre Research Institute\u2014Uganda, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2546-1068","authenticated-orcid":true,"given":"Joyce","family":"Kambugu","sequence":"additional","affiliation":[{"name":"Uganda Cancer Institute, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7472-789X","authenticated-orcid":true,"given":"Andrea M.H.","family":"Towlerton","sequence":"additional","affiliation":[{"name":"Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3340-360X","authenticated-orcid":true,"given":"Camille","family":"Puronen","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6959-0924","authenticated-orcid":true,"given":"Thomas S.","family":"Uldrick","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5366-9010","authenticated-orcid":true,"given":"Jackson","family":"Orem","sequence":"additional","affiliation":[{"name":"Uganda Cancer Institute, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9570-2755","authenticated-orcid":true,"given":"Edus H.","family":"Warren","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"},{"name":"Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13885"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08772.x"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2027612"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct1114348"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150445"},{"key":"e_1_3_8_7_2","first-page":"1","article-title":"Impact of HIV infection on the clinical presentation and survival of non-Hodgkin lymphoma: A prospective observational study from Botswana","volume":"4","author":"Milligan MG","year":"2018","unstructured":"Milligan MG, Bigger E, Abramson JS, et al: Impact of HIV infection on the clinical presentation and survival of non-Hodgkin lymphoma: A prospective observational study from Botswana. J Glob Oncol 4:1-11, 2018","journal-title":"J Glob Oncol"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2005.05.007"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/GO.20.00091"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/GO.20.00436"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(21)00181-9"},{"key":"e_1_3_8_12_2","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.3324\/haematol.2017.173583","article-title":"Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: The randomized MabEase study","volume":"102","author":"Lugtenburg P","year":"2017","unstructured":"Lugtenburg P, Avivi I, Berenschot H, et al: Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: The randomized MabEase study. Haematologica 102:1913-1922, 2017","journal-title":"Haematologica"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0610-z"},{"key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00277-017-3147-y","article-title":"SMABcare study: Subcutaneous monoclonal antibody in cancer care: Cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma","volume":"97","author":"Fargier E","year":"2018","unstructured":"Fargier E, Ranchon F, Huot L, et al: SMABcare study: Subcutaneous monoclonal antibody in cancer care: Cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma. Ann Hematol 97:123-131, 2018","journal-title":"Ann Hematol"},{"key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"e0261336","DOI":"10.1371\/journal.pone.0261336","article-title":"Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma","volume":"17","author":"Harvey MJ","year":"2022","unstructured":"Harvey MJ, Zhong Y, Morris E, et al: Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma. PLoS One 17:e0261336, 2022","journal-title":"PLoS One"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw685"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e3181b9c5ec"},{"key":"e_1_3_8_19_2","doi-asserted-by":"crossref","unstructured":"Wickham H: ggplot2: Elegant Graphics for Data Analysis (ed 2). Houston Tx Springer 2016","DOI":"10.1007\/978-3-319-24277-4_9"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60313-X"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad069"},{"key":"e_1_3_8_23_2","doi-asserted-by":"crossref","first-page":"a104","DOI":"10.4102\/sajo.v4i0.104","article-title":"Diffuse large B-cell lymphoma in a high human immunodeficiency virus (HIV) prevalence, low-resource setting","volume":"4","author":"Magangane PS","year":"2020","unstructured":"Magangane PS, Mohamed Z, Naidoo R: Diffuse large B-cell lymphoma in a high human immunodeficiency virus (HIV) prevalence, low-resource setting. S Afr J Oncol 4:a104, 2020","journal-title":"S Afr J Oncol"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30078-9"},{"key":"e_1_3_8_25_2","doi-asserted-by":"crossref","first-page":"2284047","DOI":"10.1080\/16078454.2023.2284047","article-title":"Clinical efficacy and safety of subcutaneous rituximab in non-Hodgkin lymphoma: A systematic literature review and meta-analysis","volume":"28","author":"Si T","year":"2023","unstructured":"Si T, Ma X, Zhu W, et al: Clinical efficacy and safety of subcutaneous rituximab in non-Hodgkin lymphoma: A systematic literature review and meta-analysis. Hematology 28:2284047, 2023","journal-title":"Hematology"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)00004-1"},{"key":"e_1_3_8_27_2","doi-asserted-by":"crossref","first-page":"5581772","DOI":"10.1155\/2022\/5581772","article-title":"Safety and efficacy of subcutaneous rituximab in previously untreated patients with CD20+ diffuse large B-cell lymphoma or follicular lymphoma: Results from an Italian phase IIIb study","volume":"2022","author":"Petrini M","year":"2022","unstructured":"Petrini M, Gaidano G, Mengarelli A, et al: Safety and efficacy of subcutaneous rituximab in previously untreated patients with CD20+ diffuse large B-cell lymphoma or follicular lymphoma: Results from an Italian phase IIIb study. Adv Hematol 2022:5581772, 2022","journal-title":"Adv Hematol"},{"key":"e_1_3_8_28_2","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1182\/blood-2023-189126","article-title":"Rituximab is associated with an increased risk of malaria infection in a malaria-endemic region","volume":"142","author":"Eastburg L","year":"2023","unstructured":"Eastburg L, Forconi C, Makhijani S, et al: Rituximab is associated with an increased risk of malaria infection in a malaria-endemic region. Blood 142:3126, 2023","journal-title":"Blood"}],"container-title":["JCO Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/GO-24-00489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T20:00:50Z","timestamp":1743796850000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/GO-24-00489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1200\/GO-24-00489"],"URL":"https:\/\/doi.org\/10.1200\/go-24-00489","relation":{},"ISSN":["2687-8941"],"issn-type":[{"value":"2687-8941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2024-09-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2400489"}}